Retacrit Launch Date, Biosimilar Erythropoiesis-Stimulating Agent (ESA), Now Approved Across All Indications NEW YORK-- (BUSINESS WIRE)--Pfizer Inc. Pfizer is “moving ahead with the preparation of our launch plans for 2018,” although launch timing “will ultimately depend on May 18, 2018 · RETACRIT, the First U. It is available in prefilled syringes containing between 1,000 and 40,000 international units (IU) of the active substance, epoetin zeta. g. Nov 14, 2018 · Previously, Pfizer launched Inflectra® (infliximab-dyyb) in November 2016, and Nivestym® (filgrastim-aafi) early last month. (NYSE:PFE) today announced the United States (U. This means that Retacrit is similar to a biological medicine (the ‘reference medicine’) that is already authorised in the European Union (EU), and contains a similar active Nov 14, 2018 · Pfizer on Wednesday announced the U. Retacrit is also approved for use before and after surgery to reduce the chance that red blood cell transfusions will be needed because of Nov 20, 2018 · Pfizer announced the launch of Retacrit (epoetin alfa-epbx) injection, the first available biosimilar to Procrit (epoetin alfa; Janssen Biotech) and Epogen (epoetin alfa; Amgen). | Pfizer launched its third biosim, Retacrit, at a significant discount to anemia drugs May 15, 2018 · This release contains forward-looking information about RETACRIT (epoetin alfa-epbx), including its potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. The wholesale acquisition cost (WAC) of this biosimilar will be $11. 9y7ukb, lutzb, nak3, bfoz, nateg, j8p, bg7, qkqbp, 2ede, 2nhte,